Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexigen Therapeutics Inc.

www.orexigen.com

Latest From Orexigen Therapeutics Inc.

If Orexigen Disappears, Who's Left In The Obesity Market?

Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.

Business Strategies Commercial

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Opioid Warning Letter To Cipher Likely Easy Call For US FDA

Murky enforcement environment has probably contributed to FDA's record-low number of letters, but detailing material for ConZip failed to include risk information and important limitations of use for the tramadol extended-release product.

Advertising, Marketing & Sales Drug Safety

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orexigen Therapeutics Inc.
  • Senior Management
  • Michael Narachi, Pres. & CEO
    Jason Keyes, SVP, CFO
    Thomas Cannell, EVP, COO & Pres., Global Commercial Products
    Peter Flynn, SVP & Head, Dev., Regulatory Affairs & Safety
  • Contact Info
  • Orexigen Therapeutics Inc.
    Phone: (858) 875-8600
    3344 N. Torrey Pines Ct., Ste. 200
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register